Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Using Transcranial Electrostimulation (TESA-HB) Therapy for the Treatment of Depressive Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18-65 years old on enrollment~* Assessed by Evaluator with mild to moderate depressive episode, based on the MDI Rating Scale (20-24 mild; 25-29 moderate).~* Have average MDI pain rating score of \> 20 or \<29 during baseline~* Assessed by Evaluator to have mild to moderate depressive episode, based on the HAM-D21 Rating Scale (8-13 = mild; 14-17 moderate).~* Assessed by Evaluator to have mild to moderate depressive episode based on ICD-10 Diagnostic Guidelines 1,2~* Willing and able to visit 2 weeks ( 5 times per week) as a clinic outpatient to participate in this clinical investigation~* Willing and able to return to the clinic for evaluation during the follow up period - 2 weeks, 1 month (4 wks), 2 months (8 wks), and 3 months (12wks) following the completion of TESA-HB Therapy~* Willing to be monitored, fill out daily medication logs, and appear for all physician visits for baseline, treatment and follow-up period~* English speaking and able to understand and approve the consent form, and understand and provide answers on the Depression and Anxiety assessment form and the Psychological General Well-Being Index (PGWB-S) questionnaires~Exclusion Criteria:• MDI Rating Scale of \< 20 or \> 29~* High variability in baseline MDI scores (changes more than 30%)~* HAM-D21 Rating Scale of \< 8 or \> 17~* Assessed outside of mild to moderate depression episode range based on the ICD-10 Diagnostic Guidelines 1,2~* Recent history of taking Antidepressant or Antianxiety medication within 3 months prior to baseline~* Is pregnant, or may be pregnant, or plans to become pregnant during the study period~* Sensitivity to electrodes and/or their conductive gels or adhesives~* Break in skin integrity at the areas of electrode placement~* Currently suspected use of narcotic~* Presence of any implanted electronic device, cardiac stimulator, or pacemaker~* History of brain injury, including seizures, epilepsy, stroke, tumor of central nervous system, or hydrocephalus~* Acute brain injuries, infections or tumor of central nervous system~* History of heart attacks within 1year congestive heart failure~* Blood pressure: \> 140 systolic and/or \> 90 diastolic~* History of schizophrenia~* Previous experience with Cranial Electrotherapy Stimulator (CES) devices~* Failure to complete 80% of daily medication logs or complete a questionnaire and two physician assessments during baseline period~* Failed to complete 75% of follow up visits or failed to complete more than 2 treatments will be excluded in the per-protocol (PP) analysis~* Acute psychiatric disorders (other than depression, insomnia and/or anxiety)~* Use of psychoactive drugs (other than antidepressants and/or anxiety)~* These subjects will continue to be followed in the study, but will be classified in the intent-to-treat (ITT) group~* HRHS employees, in an effort to protect their privacy, as the study will be conducted in a Holy Redeemer facility. Additionally, this exclusion was decided upon to minimize the possibility of coercion or undue influence in relationship with Holy Redeemer employees.~* Illiterate persons, as the study requires completion of assessments tools in the home setting where the subject may/may not have assistance with reading and understanding the tools, study documents and proceedures as required.~* Uninsured persons, to financially protect them in the rare instance that medical care would be required as a result of the study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Arm A (Type: EXPERIMENTAL): TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).